Research analysis

Zhongshan Hospital in Shanghai is running an early-phase single-arm trial of a banked cell product: endocrine cells isolated from resected pancreas, expanded ex vivo into organoid-like structures, HLA-typed, cryobanked, and infused into the portal vein of patients whose diabetes follows total pancreatectomy. The design is a Simon two-stage plan that counts success as thirty percent of patients, and every load-bearing question is about what expansion does to a beta cell.

A study at Assistance Publique Hopitaux de Marseille recruits sixty adults with Crohn's disease or ulcerative colitis and grows organoids from inflamed and non-inflamed mucosa of the same patient, alongside non-IBD controls. Its primary question is whether the inflamed epithelium's repair defect is cell-intrinsic and persists in culture, and its CRISPR arm turns the same patient cells into a causal drug-target testbed.

NCT07697716, the PRECISE-EGFR study at Gemelli in Rome led by E. Bria, will build paired cell-culture and organoid models from residual samples of thirty EGFR-mutant NSCLC patients. Its registered goal is deliberately modest, model generation and tumor concordance, and that modesty is either its strength or its escape hatch.

NCT06603506, the PENDOR pilot at Centre Francois Baclesse in Caen, is recruiting sixteen women with high-risk localized endometrial cancer to build organoids usable for PARP inhibitor response assays. Its cohort design quietly reveals a mechanism-guided bet on synthetic lethality, while its title promises efficacy work the registry never registers.

NCT07709052 at IRCCS Saverio de Bellis in Italy plans organoid and tumorsphere models from resected IPMN, PanIN, and PDAC tissue to find biomarkers that predict progression to pancreatic cancer. The design is the only practical route to PanIN material, but every lesion enters through a surgical door that selects for the aggressive end of the spectrum.

Two single-arm trials from one Chengdu center use tumor-derived organoids to pick therapy for locally advanced and anaplastic thyroid cancer. One started three and a half years before it was registered; the other has never recruited nor been updated.

NCT06702800 tops organoid drug-sensitivity rankings on the strength of a title. Read line by line, the registry record contains no simulation, no comparator, and an outcome window that opened before the trial was posted.

The ColoPan study at the Luxembourg Institute of Health is one of the few registry records that treats an organoid-based drug-testing platform as something to be credentialed rather than assumed. Its own endpoint definitions are the first test.

A basic-science study at three French centers plans to derive iPSC lines and intestinal organoids from an estimated four children with pediatric intestinal pseudo-obstruction, each carrying a different ACTG2 variant, and trace how each mutation derails smooth muscle development. It is the most honest possible version of a genre the organoid field keeps fumbling: using a dish model as a variant classifier, with the sample size of a case series and the ambition of a screening platform.

A new observational study at Ospedale Maggiore Policlinico in Milan will apply purified IgG from myasthenia gravis patients to healthy-donor neuromuscular organoids, hunting for the structural and electrical signature of refractory disease. Its deeper bet is that an in vitro junction, soaked in patient antibody and human complement, can settle a question the clinic cannot: whether treatment-resistant myasthenia is irreversible end-plate damage.

A single-group study at Ospedale Maggiore Policlinico in Milan cultures liver organoids with stellate cells into assembloids, overloads them with fat, fructose, and cholesterol, and compares tissue with and without the PNPLA3 I148M variant to model the earliest phase of steatohepatitis. One of its objectives is to test antisense oligonucleotides against PNPLA3 in human tissue before they reach patients, but that objective has no endpoint of its own in the registry.

A retrospective cohort at Eastern Hepatobiliary Surgery Hospital in Shanghai classified 122 resected liver-cancer patients as organoid drug-sensitive or drug-resistant by IC50 cutpoint, then asked whether the split predicts recurrence after adjuvant TACE. The design captures something real about chemotherapy, but the therapy it claims to predict is half ischemia, and no dish models that.

A federal grant record describes MTDIA, a transition-state inhibitor of the enzyme MTAP, tested in mice, a human PDX model, and human colon tumor organoids against inflammation-associated colorectal cancer. It bets that raising the metabolite MTA is protective, which is the exact inverse of the synthetic-lethal MTAP strategy most of oncology is pursuing, and the tension between those two bets is where the organoid science gets interesting.

A single-arm trial at Henan Cancer Hospital plans to enroll 20 patients with recurrent small cell lung cancer, culture organoids from biopsy, pick the most sensitive marketed drug, and measure objective response. It is a feasibility study of a concierge model of functional precision oncology, and everything that will be concluded from its results exceeds what 20 uncontrolled patients can support.

A prospective study at IRCCS ICS Maugeri in Pavia will use breast cancer patient-derived organoids as a controlled source of extracellular vesicles, testing them as carriers of indocyanine green contrast for fluorescence-guided surgery. The registered primary endpoint is simply whether the organoids grow, which says a lot about how far the concept still has to travel.

A recruiting observational study led by Chungnam National University Hospital is testing whether glioblastoma organoid drug sensitivity scores recapitulate real patient outcomes, with a registered ambition that goes well beyond personalization: determining whether the model could eventually replace clinical trials. The design choices, including temozolomide as the calibration standard, are worth reading closely.

A single-center trial registered in April 2026 at Shanghai Children's Medical Center will use patient-derived organoid drug sensitivity testing to pick chemotherapy for 30 children with relapsed or refractory soft tissue sarcoma. The study is single-arm, open-label, and feasibility-framed, and that design choice is the real story.

Single-cell studies of human alveolar capillary dysplasia and FOXF1 vessel organoids show that alveolar type 1 epithelial maturation depends on TGF-beta2 signaling from capillary aerocytes. The finding relocates the lung organoid maturation problem from the epithelium to the vasculature.

A ClinicalTrials.gov-registered study at Peking Union Medical College Hospital will randomize 128 patients with relapsed extensive-stage small cell lung cancer to organoid-guided drug selection or standard topotecan. The trial has not started recruiting, but its randomized design already says something important about where organoid-guided medicine stands.

Guillen et al. built organoids from patient-derived xenografts (PDxOs) and validated organoid drug predictions in the matching PDX models. The platform is credible precisely because it submits to an in vivo checkpoint, and its own data show how narrow short-term organoid assays are.

Pietrantonio, Sottoriva and colleagues profiled chromatin accessibility and transcriptome at single-cell resolution across 37 colorectal cancer patients, catalogued recurrent epigenetic alterations, and functionally tested them with CRISPRi in four patient-derived organoids. The screen found new cancer dependencies - and a quieter result with bigger consequences for organoid drug screening: only a third to 43 percent of tissue chromatin alterations survive in culture.

HIPANC-002, a Swiss observational study due to start at Klinik Hirslanden in Zurich, will grade the commercial OncoTreat and OncoTarget transcriptome tests against patient-derived organoids and patient progression-free survival in 185 metastatic pancreatic cancer cases. Both tests are explicitly non-interventional. The study will generate the largest head-to-head molecular-versus-functional comparison in the field - and its correlation-first design shows exactly what such evidence can and cannot prove.

NCT06332716 registers an organoid drug-sensitivity-guided study for esophageal, gastric, colorectal and stromal tumours as a Phase 3, non-randomized, parallel trial with a historical control arm. Its own detailed description calls it a single-arm exploratory study with no sample-size estimate, its completion date passed in 2025, and its status is now UNKNOWN. The record is a lesson in what trial labels can and cannot certify.

A UT Health San Antonio observational study with NCI support has spent eight years building a living lung cancer organoid biobank paired with circulating tumor cells. It is unglamorous, underpowered per stratum, and possibly the most-cited kind of organoid work there is.